Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children
Zavadenko, N.N.; Suvorinova, N.Iu.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(7): 43-47
2008
ISSN/ISBN: 1997-7298 PMID: 18833117 Document Number: 620073
Therapeutic effect of atomoxetine and piracetam has been assessed in the open controlled study included 42 patients with attention deficit hyperactivity disorder (ADHD), aged from 6 to 13 years. Group 1 (16 patients) received atomoxetine (strattera) in daily dosage 0,8-1,2 mg/kg as a monotherapy for 6 weeks. Patients of group 2 (14 children) received piracetam as a monotherapy in daily dosage 50-70 mg/kg for 6 weeks. No pharmacological therapy was conducted in group 3 (a control one) which included 12 patients with ADHD. The high effectiveness of both atomoxetine and piracetam has been shown. However, comparing to piracetam, the therapeutic effect of atomoxetine was reached earlier (two weeks after the beginning of therapy) and was more pronounced for all components of syndromes.